Evaxion Biotech A/SEVAX
13F holders, Q3 2025 (September 30)2holders
0new positions
0sold out
$3.76avg. 13F price*
At the end of Q3 2025, 2 institutions reported holding Evaxion Biotech A/S (EVAX) in their 13F filings, unchanged from Q2 2025. 0 opened new positions and 0 sold out. The largest holders were Merck & Co., Inc. ($4.6M) and Rhumbline Advisers ($7).
- Company
- Evaxion Biotech A/S
- CUSIP
- 29970R204
- Latest filing quarter
- Q1 2026
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 0 | $0 |
Ownership 2 holders
| Merck & Co., Inc. | 2.00% | No change | 1,214,126 | $4.6M |
| Rhumbline Advisers | 0.00% | No change | 2 | $7 |
"% of holder's portfolio" is EVAX's weight in each manager's 13F, not the share of Evaxion Biotech A/S the manager owns.